Cargando…

Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France

OBJECTIVE: To compare the natural history of familial transthyretin amyloid polyneuropathies (FAP) due to the Val30Met, Ser77Tyr, and Ile107Val mutations in France with the classical Portuguese Val30Met FAP. METHODS: We compared 84 French patients with a control group of 110 Portuguese patients carr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mariani, Louise‐Laure, Lozeron, Pierre, Théaudin, Marie, Mincheva, Zoia, Signate, Aissatou, Ducot, Beatrice, Algalarrondo, Vincent, Denier, Christian, Adam, Clovis, Nicolas, Guillaume, Samuel, Didier, Slama, Michel S., Lacroix, Catherine, Misrahi, Micheline, Adams, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4738459/
https://www.ncbi.nlm.nih.gov/pubmed/26369527
http://dx.doi.org/10.1002/ana.24519
_version_ 1782413616001056768
author Mariani, Louise‐Laure
Lozeron, Pierre
Théaudin, Marie
Mincheva, Zoia
Signate, Aissatou
Ducot, Beatrice
Algalarrondo, Vincent
Denier, Christian
Adam, Clovis
Nicolas, Guillaume
Samuel, Didier
Slama, Michel S.
Lacroix, Catherine
Misrahi, Micheline
Adams, David
author_facet Mariani, Louise‐Laure
Lozeron, Pierre
Théaudin, Marie
Mincheva, Zoia
Signate, Aissatou
Ducot, Beatrice
Algalarrondo, Vincent
Denier, Christian
Adam, Clovis
Nicolas, Guillaume
Samuel, Didier
Slama, Michel S.
Lacroix, Catherine
Misrahi, Micheline
Adams, David
author_sort Mariani, Louise‐Laure
collection PubMed
description OBJECTIVE: To compare the natural history of familial transthyretin amyloid polyneuropathies (FAP) due to the Val30Met, Ser77Tyr, and Ile107Val mutations in France with the classical Portuguese Val30Met FAP. METHODS: We compared 84 French patients with a control group of 110 Portuguese patients carrying the Val30Met mutation also living in France, all referred to and followed at the French National FAP Reference Center from 1988 to 2010. Clinical examination, functional and walking disability scores, nerve conduction studies, and muscle biopsies are reported. We also conducted a comprehensive literature review to further determine the range of phenotypic expression. RESULTS: By comparison with Portuguese Val30Met FAP, French Ile107Val, Ser77Tyr, and LateVal30Met FAP showed more rapid and severe disease progression; onset of gait disorders was 3 times more rapid (p < 0.0001) and the rate of modified Norris test decline was up to 40 times faster in Ile107Val patients (p < 0.0001). Median survival was much shorter in Ile107Val and in Val30Met mutation with late onset (>50 years; LateMet30) FAP (p = 0.0005). Other distinctive features relative to the Portuguese patients included atypical clinical presentations, demyelination on nerve conduction studies (p = 0.0005), and difficult identification of amyloid deposits in nerve and muscle biopsies. INTERPRETATION: Ile107Val and LateMet30 mutations are associated with the most debilitating and severe FAP ever described, with rapid onset of tetraparesis and shorter median survival. It could be explained by frequent large‐fiber involvement and associated demyelination and more severe axonal loss. These findings have major implications for genetic counseling and patient management as new therapeutic options are being assessed in clinical trials (TTR gene silencing). Ann Neurol 2015;78:901–916
format Online
Article
Text
id pubmed-4738459
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-47384592016-02-12 Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France Mariani, Louise‐Laure Lozeron, Pierre Théaudin, Marie Mincheva, Zoia Signate, Aissatou Ducot, Beatrice Algalarrondo, Vincent Denier, Christian Adam, Clovis Nicolas, Guillaume Samuel, Didier Slama, Michel S. Lacroix, Catherine Misrahi, Micheline Adams, David Ann Neurol Research Articles OBJECTIVE: To compare the natural history of familial transthyretin amyloid polyneuropathies (FAP) due to the Val30Met, Ser77Tyr, and Ile107Val mutations in France with the classical Portuguese Val30Met FAP. METHODS: We compared 84 French patients with a control group of 110 Portuguese patients carrying the Val30Met mutation also living in France, all referred to and followed at the French National FAP Reference Center from 1988 to 2010. Clinical examination, functional and walking disability scores, nerve conduction studies, and muscle biopsies are reported. We also conducted a comprehensive literature review to further determine the range of phenotypic expression. RESULTS: By comparison with Portuguese Val30Met FAP, French Ile107Val, Ser77Tyr, and LateVal30Met FAP showed more rapid and severe disease progression; onset of gait disorders was 3 times more rapid (p < 0.0001) and the rate of modified Norris test decline was up to 40 times faster in Ile107Val patients (p < 0.0001). Median survival was much shorter in Ile107Val and in Val30Met mutation with late onset (>50 years; LateMet30) FAP (p = 0.0005). Other distinctive features relative to the Portuguese patients included atypical clinical presentations, demyelination on nerve conduction studies (p = 0.0005), and difficult identification of amyloid deposits in nerve and muscle biopsies. INTERPRETATION: Ile107Val and LateMet30 mutations are associated with the most debilitating and severe FAP ever described, with rapid onset of tetraparesis and shorter median survival. It could be explained by frequent large‐fiber involvement and associated demyelination and more severe axonal loss. These findings have major implications for genetic counseling and patient management as new therapeutic options are being assessed in clinical trials (TTR gene silencing). Ann Neurol 2015;78:901–916 John Wiley and Sons Inc. 2015-10-07 2015-12 /pmc/articles/PMC4738459/ /pubmed/26369527 http://dx.doi.org/10.1002/ana.24519 Text en © 2015 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Mariani, Louise‐Laure
Lozeron, Pierre
Théaudin, Marie
Mincheva, Zoia
Signate, Aissatou
Ducot, Beatrice
Algalarrondo, Vincent
Denier, Christian
Adam, Clovis
Nicolas, Guillaume
Samuel, Didier
Slama, Michel S.
Lacroix, Catherine
Misrahi, Micheline
Adams, David
Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France
title Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France
title_full Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France
title_fullStr Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France
title_full_unstemmed Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France
title_short Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France
title_sort genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in france
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4738459/
https://www.ncbi.nlm.nih.gov/pubmed/26369527
http://dx.doi.org/10.1002/ana.24519
work_keys_str_mv AT marianilouiselaure genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance
AT lozeronpierre genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance
AT theaudinmarie genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance
AT minchevazoia genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance
AT signateaissatou genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance
AT ducotbeatrice genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance
AT algalarrondovincent genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance
AT denierchristian genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance
AT adamclovis genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance
AT nicolasguillaume genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance
AT samueldidier genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance
AT slamamichels genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance
AT lacroixcatherine genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance
AT misrahimicheline genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance
AT adamsdavid genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance
AT genotypephenotypecorrelationandcourseoftransthyretinfamilialamyloidpolyneuropathiesinfrance